These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 36045701

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M, Heumann T, Goff L, Agarwal R.
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
    Aimar G, Paratore C, Zichi C, Marino D, Sperti E, Caglio A, Gamba T, De Vita F, Di Maio M.
    Explor Target Antitumor Ther; 2021 Apr; 2(5):448-464. PubMed ID: 36045702
    [Abstract] [Full Text] [Related]

  • 9. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
    Rizzo A, Federico AD, Ricci AD, Frega G, Palloni A, Pagani R, Tavolari S, Marco MD, Brandi G.
    Cancer Control; 2020 Apr; 27(1):1073274820983013. PubMed ID: 33356500
    [Abstract] [Full Text] [Related]

  • 10. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
    Rizzo A, Brandi G.
    Cancer Treat Res Commun; 2021 Apr; 27():100354. PubMed ID: 33756174
    [Abstract] [Full Text] [Related]

  • 11. Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures.
    Rizzo A, Tavolari S, Ricci AD, Frega G, Palloni A, Relli V, Salati M, Fenocchio E, Massa A, Aglietta M, Brandi G.
    Cancers (Basel); 2020 Nov 04; 12(11):. PubMed ID: 33158162
    [Abstract] [Full Text] [Related]

  • 12. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W, Hu Z, Song J, Wu Y, Zhang B, Zhang L.
    Front Biosci (Landmark Ed); 2022 Jun 08; 27(6):185. PubMed ID: 35748261
    [Abstract] [Full Text] [Related]

  • 13. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG, Zeng TM, Tao CJ.
    Hepatobiliary Pancreat Dis Int; 2022 Oct 08; 21(5):440-449. PubMed ID: 36115807
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.
    Chakrabarti S, Kamgar M, Mahipal A.
    Cancers (Basel); 2020 Jul 24; 12(8):. PubMed ID: 32722188
    [Abstract] [Full Text] [Related]

  • 17. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
    Rizzo A, Ricci AD, Brandi G.
    Cancer Treat Res Commun; 2021 Jul 24; 27():100356. PubMed ID: 33799004
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Precision Oncology Targets in Biliary Tract Cancer.
    Farha N, Dima D, Ullah F, Kamath S.
    Cancers (Basel); 2023 Mar 31; 15(7):. PubMed ID: 37046766
    [Abstract] [Full Text] [Related]

  • 20. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options.
    Personeni N, Lleo A, Pressiani T, Colapietro F, Openshaw MR, Stavraka C, Pouptsis A, Pinato DJ, Rimassa L.
    Cancers (Basel); 2020 Nov 13; 12(11):. PubMed ID: 33202975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.